A randomized, double-blind, placebo-controlled, parallel-design, multicenter study to investigate the efficacy and safety of Myelo001 in reducing chemotherapy-induced neutropenia

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-design, multicenter study to investigate the efficacy and safety of Myelo001 in reducing chemotherapy-induced neutropenia

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2015

At a glance

  • Drugs Myelo 001 (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Acronyms MyeloConcept
  • Most Recent Events

    • 31 Dec 2015 New trial record
    • 15 Dec 2015 Results of this trial are expected in the first half of 2017, according to a Myelo Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top